These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11569889)

  • 61. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.
    Berrak SG; Ozdemir N; Bakirci N; Turkkan E; Canpolat C; Beker B; Yoruk A
    Support Care Cancer; 2007 Oct; 15(10):1163-8. PubMed ID: 17372773
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
    Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
    Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
    Hamadani M; Awab A; Chaudhary L; Tfayli A
    J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743
    [No Abstract]   [Full Text] [Related]  

  • 65. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
    Jeremić B
    Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
    Zeidman A; Ben Dayan D; Ben Zion T; Kaufman O; Cohen AM; Mittelman M
    Haematologia (Budap); 1998; 29(1):25-31. PubMed ID: 9704254
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.
    Kris MG; Grunberg SM; Gralla RJ; Baltzer L; Zaretsky SA; Lifsey D; Tyson LB; Schmidt L; Hahne WF
    J Clin Oncol; 1994 May; 12(5):1045-9. PubMed ID: 8164028
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Droperidol and dolasetron alone or in combination for prevention of postoperative nausea and vomiting after vitrectomy.
    Eberhart LH; Morin AM; Hoerle S; Wulf H; Geldner G
    Ophthalmology; 2004 Aug; 111(8):1569-75. PubMed ID: 15288990
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
    Grote TH; Pineda LF; Figlin RA; Pendergrass KB; Hesketh PJ; Karlan BY; Reeves JA; Porter LL; Benedict CR; Hahne WF
    Cancer J Sci Am; 1997; 3(1):45-51. PubMed ID: 9072308
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The anti-emetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation.
    Or R; Drakos P; Nagler A; Naparstek E; Kapelushnik J; Cass Y
    Support Care Cancer; 1994 Jul; 2(4):245-8. PubMed ID: 8087443
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reduced resource utilization in patients treated for postoperative nausea and vomiting with dolasetron mesylate. MCPR44 Study Group.
    Kovac A; Mingus M; Sung YF; Neary M
    J Clin Anesth; 1999 May; 11(3):235-41. PubMed ID: 10434221
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Postoperative nausea and vomiting after surgery for prognathism: not only a question of patients' comfort. A placebo-controlled comparison of dolasetron and droperidol.
    Piper SN; Röhm K; Boldt J; Kranke P; Maleck W; Seifert R; Suttner S
    J Craniomaxillofac Surg; 2008 Apr; 36(3):173-179. PubMed ID: 18353666
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.
    Yeilding A; Bertoli L; Eisenberg P; Plezia P; Modiano MR; Alberts DS; Khojasteh A; Cramer MB; Hahne WF
    Am J Clin Oncol; 1996 Dec; 19(6):619-23. PubMed ID: 8931684
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.
    Oge A; Alkiş N; Oge O; Kartum A
    J Chemother; 2000 Feb; 12(1):105-8. PubMed ID: 10768522
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ondansetron and dolasetron provide equivalent postoperative vomiting control after ambulatory tonsillectomy in dexamethasone-pretreated children.
    Sukhani R; Pappas AL; Lurie J; Hotaling AJ; Park A; Fluder E
    Anesth Analg; 2002 Nov; 95(5):1230-5, table of contents. PubMed ID: 12401599
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.
    Trifilio S; Welles C; Seeger K; Mehta S; Fishman M; McGowan K; Strejcek K; Eiten E; Pirotte C; Lucier E; DeFrates S; Mehta J
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):584-589. PubMed ID: 28694084
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
    Coppes MJ; Yanofsky R; Pritchard S; Leclerc JM; Howard DR; Perrotta M; Keays S; Pyesmany A; Dempsey E; Pratt CB
    J Pediatr Hematol Oncol; 1999; 21(4):274-83. PubMed ID: 10445889
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.